Fosun Pharma pendapatan tahunan 41,7 miliar yuan: Pendapatan domestik turun 4% secara tahunan Chen Zhanyu mengundurkan diri dari jabatan CFO

雷递网 雷建平 6 April

Shanghai Fosun Pharma (Group) Co., Ltd. (Stock code: 600196, Stock abbreviation: Fosun Pharma) recently released its financial report as of December 31, 2025. The financial report shows that Fosun Pharma’s revenue in 2025 was 41.662 billion yuan, an increase of 1.45% compared to 41.067 billion yuan in the same period last year.

Fosun Pharma’s total R&D investment in 2025 reached 5.913 billion yuan, with 72.77% of the R&D investment related to innovative drugs.

Fosun Pharma’s net profit in 2025 was 3.371 billion yuan, an increase of 21.69% compared to 2.77 billion yuan in the same period last year; net profit after deducting non-recurring gains and losses was 2.34 billion yuan, up 1.12% from 2.314 billion yuan last year.

Fosun Pharma’s revenue in the fourth quarter of 2025 was 12.268 billion yuan, with a net profit of 847 million yuan, and net profit after deducting non-recurring gains and losses was 767 million yuan.

During the reporting period, the net cash flow from operating activities was 5.213 billion yuan, a year-on-year increase of 16.45%. Meanwhile, Fosun Pharma continued to promote the exit and integration of non-strategic, non-core assets, optimize asset structure, and accelerate cash inflow, with nearly 3 billion yuan of funds recovered in 2025.

Fosun Pharma’s domestic revenue in 2025 was 28.7 billion yuan, a decrease of 4% year-on-year.

Fosun Pharma’s pharmaceutical revenue in 2025 was 29.833 billion yuan, an increase of 3.14% compared to 28.924 billion yuan last year, accounting for 71.61% of total revenue.

Among them, Fosun Pharma’s revenue from innovative drugs in 2025 was 9.893 billion yuan, a 29.59% increase year-on-year, accounting for 23.75% of total revenue, an increase of 5.16 percentage points compared to last year, and accounting for 33.16% of pharmaceutical business revenue, an increase of 6.77 percentage points.

The growth rates of Perjeta (pertuzumab injection), Aokangze (natalizumab capsules), Yikeda (Acilumumab injection) exceeded 30%. Revenue from Hanlikang (rituximab injection), Hanquyou (trastuzumab injection), Hanszhuang (sulrili monoclonal antibody injection) remained stable.

Fosun Pharma’s revenue from medical devices and medical diagnostics in 2025 was 4.321 billion yuan, a decrease of 0.05% compared to 4.323 billion yuan last year, accounting for 10.37% of total revenue.

Fosun Pharma’s revenue from healthcare services in 2025 was 7.373 billion yuan, down 3.58% from 7.647 billion yuan last year, accounting for 17.7%.

Fosun Pharma’s revenue in Mainland China in 2025 was 28.685 billion yuan, a decrease of 3.64% compared to 29.77 billion yuan last year, accounting for 68.85%.

Fosun Pharma’s overseas revenue in 2025 was 12.977 billion yuan, an increase of 14.87% compared to 11.3 billion yuan last year, accounting for 31.15% of operating income, with a 3.64 percentage point increase compared to last year.

CFO Chen Zhanyu resigned, Huang Zhi appointed

Recently, Fosun Pharma announced that the board of directors received a written resignation letter from Chen Zhanyu. Due to work arrangement adjustments, Chen Zhanyu applied to resign from the position of Chief Financial Officer, effective April 2, 2026.

After the resignation takes effect, Chen Zhanyu will continue to serve as Senior Vice President of the company. On April 2, 2026, upon nomination by the CEO, the board of directors approved the appointment of Huang Zhi as Senior Vice President and Chief Financial Officer of the company, with a term starting from April 2, 2026, until the expiration of the current board.

Huang Zhi, holding permanent residence in the United States, joined Fosun Pharma in February 2026 (including Fosun Pharma and its holding subsidiaries/units), currently serving as Senior Vice President, Chief Financial Officer, and Co-President of the Innovative Drugs Division.

Before joining the group, Huang Zhi mainly engaged in financial-related work. From April 2007 to October 2020, he held positions such as Business Planning and Analysis Manager for Novartis AG (stock code: NVS.NYS) Oncology Division in the US, Head of Finance for Western China, Head of Business Processes and Controls in Greater China, Head of Business Planning and Analysis in Greater China, and Chief Financial Officer for South Korea; from October 2020 to February 2025, he served as Chief Financial Officer for Greater China, Asia-Pacific (excluding China), Global Technology Operations, and Innovation Center at BeiGene, during which he was Global Business Finance Head from June 2023 to February 2025; from May 2025 to January 2026, he served as Senior Vice President of Corporate Development & Finance at Ascletis Pharma (Stock code: 6855.HK, AAPG.NASDAQ).

Guo Guangchang controls 36% of shares

As of December 31, 2025, Shanghai Fosun High Technology (Group) Co., Ltd. held 33.32%, HKSCC NOMINEES LIMITED held 20.65%, Hong Kong Central Clearing Co., Ltd. held 1.94%, China Securities Finance Corporation held 1.45%;

As of December 31, 2025, Fosun Pharma’s shareholding structure

Industrial and Commercial Bank of China – Huatai-PineBridge CSI 300 ETF held 0.79%, Bank of China – China Merchants CSI Biotech Index ETF held 0.7%, China Construction Bank – E Fund CSI 300 Healthcare ETF held 0.64%;

Bank of Shanghai – Yinhua CSI Innovation Drug Industry ETF held 0.58%, China Construction Bank – E Fund CSI 300 ETF held 0.56%, Guo Guangchang held 0.52%.

Fosun controls 72.5% of Fosun International, which in turn controls 100% of Fosun High Technology. Guo Guangchang and Wang Qunbin are the controllers of Fosun International.

Guo Guangchang owns 85.29% of Fosun International, Wang Qunbin owns the remaining 14.71%. Fosun International owns 100% of Fosun High Technology, Fosun High Technology owns 36% of Fosun Pharma, including approximately 33.32% directly held by Fosun High Technology and about 2.68% held via HKSCC NOMINEES LIMITED.

As of today’s close, Fosun Pharma’s stock price was 26.68 yuan, with a market value of 71.2 billion yuan.